EARLY INTERVENTION IN SCHIZOPHRENIA

精神分裂症的早期干预

• 批准号: 3442832
• 负责人: ANDREA BLANCH
• 金额: $ 26.56万
• 依托单位: NEW YORK STATE OFFICE OF MENTAL HEALTH
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-03-01 至 1994-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3442832
• 关键词: community mental health services; computer data analysis; data collection; disease /disorder proneness /risk; drug adverse effect; family structure /dynamics; family therapy; group therapy; health care cost /financing; health education; health service demonstration project; hospital utilization; human subject; human therapy evaluation; mental disorder chemotherapy; mental disorder diagnosis; mental disorder prevention; mental health counseling; mental health facility; psychotherapy; quality of life; questionnaires; relapse /recurrence; schizophrenia; sign /symptom; social adjustment; social support network

The purpose of this demonstration project is to determine whether an Early Intervention Strategy is effective in reducing relapse and rehospitalization rates in schizophrenic patients who have recently been discharged from the hospital and are at high risk for relapse. Patients will be randomly assigned to an experimental and control group: The Early Intervention Strategy experimental group will receive 1) Education of patients and family members about prodromal symptoms of relapse and 2) Immediate intervention with increased medication and supportive crisis therapy when prodromal symptoms appear until the episode resolves. There is close collaboration between patients, family members, and treatment personnel. The control group will receive Treatment as Usual (individual medication management and support bi-weekly) as outpatients. The relative efficacy of these two treatment programs will be compared over an 18-month period with respect to relapse and rehospitalization rates, major dimensions of psychopathology, social and vocational role functioning, family burden, patient and family satisfaction, patient quality of life, drug side effects and cost effectiveness. It is hypothesized that 1) The rates of relapse and rehospitalization will be statistically significantly higher for patients in the Treatment as Usual Group as compared to patients in the Early Intervention Strategy Group after 18 months. 2) Patients in the Early Intervention Strategy Group will have significantly decreased symptomatology, better social and vocational role functioning, decreased drug side effects, better quality of life, and more satisfaction with treatment, and families will show decreased family burden and more satisfaction with treatment than those in the Treatment as Usual Group. 3) It will be significantly less costly to treat patients in the Early Intervention Strategy Group than the Treatment as Usual Group, the main reason being much reduced hospitalization in the EIS group. Significance: If relapse and rehospitalization rates in schizophrenic patients can be reduced, it will be a great public health benefit and patients will have a sense of control over the course of their illness.

该示范项目的目的是确定早期 干预策略有效减少复发， 精神分裂症患者的再住院率， 出院后复发的风险很高。 患者 将被随机分配到实验组和对照组： 干预策略实验组将接受1） 患者和家庭成员关于复发的前驱症状和2） 立即干预，增加药物和支持危机 当前驱症状出现时进行治疗，直到发作消退。 那里 是患者、家庭成员和治疗之间的密切合作 人员的 对照组将接受个体化治疗 药物管理和支持，每两周一次）作为门诊病人。 的相对 这两种治疗方案的疗效将在18个月内进行比较 复发率和再住院率，主要 精神病理学、社会和职业角色功能的维度， 家庭负担，患者和家庭满意度，患者生活质量， 药物副作用和成本效益。 假设1）复发率和再住院率将 治疗组患者的统计学显著性更高， 与早期干预策略中的患者相比， 18个月后组。 2)早期干预策略中的患者 组将有显着减少的精神病学，更好的社会和 职业角色功能，减少药物副作用，更好的 生活，更满意的治疗，和家庭将显示 家庭负担减轻，对治疗的满意度高于 治疗组作为对照组。 3)这将大大降低成本， 早期干预策略组患者的治疗 主要原因是， EIS组。 精神分裂症患者的复发率和再住院率 病人可以减少，这将是一个巨大的公共卫生利益， 病人会对自己的病情有一种控制感。